Quadramet (Page 4 of 6)

INFORMATION FOR PATIENTS

Patients who receive QUADRAMET® should be advised that for several hours following administration, radioactivity will be present in excreted urine. To help protect themselves and others in their environment, precautions need to be taken for 12 hours following administration. Whenever possible, a toilet should be used, rather than a urinal, and the toilet should be flushed several times after each use. Spilled urine should be cleaned up completely and patients should wash their hands thoroughly. If blood or urine gets onto clothing, the clothing should be washed separately, or stored for 1-2 weeks to allow for decay of the Sm-153.

Some patients have reported a transient increase in bone pain shortly after injection (flare reaction). This is usually mild and self-limiting and occurs within 72 hours of injection. Such reactions are usually responsive to analgesics.

Patients who respond to QUADRAMET® might begin to notice the onset of pain relief one week after QUADRAMET®. Maximal pain relief generally occurs at 3-4 weeks after injection of QUADRAMET®. Patients who experience a reduction in pain may be encouraged to decrease their use of opioid analgesics.

LABORATORY TESTS

Because of the potential for bone marrow suppression, beginning 2 weeks after QUADRAMET® administration, blood counts should be monitored weekly for at least 8 weeks, or until recovery of adequate bone marrow function.

In a subset of 31 patients who had serum calcium monitored during the first 2 hours after QUADRAMET® infusion, a clear pattern of calcium change was not identified. However, 10 (32%) patients had at least one serum calcium level that was below normal (7.16 to 8.28). The extent to which samarium-153-EDTMP is related to this hypocalcemia is not known. Caution should be exercised when administering QUADRAMET® to patients at risk for developing hypocalcemia.

DRUG INTERACTIONS

The potential for additive bone marrow toxicity of QUADRAMET® with chemotherapy or external beam radiation has not been studied. QUADRAMET® should not be given concurrently with chemotherapy or external beam radiation therapy unless the benefit outweighs the risks. QUADRAMET® should not be given after either of these treatments until there has been time for adequate marrow recovery. (See Warnings Section).

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

Carcinogenesis in humans given EDTMP, in QUADRAMET® , is not likely. Osteosarcomas occurred in a 2-year toxicity/carcinogenicity study of EDTMP administered by gastric intubation to Sprague-Dawley rats, in male rats at 50 mg/kg/day and in male and female rats at 150 mg/kg/day (the dosage was increased to 333 mg/kg/day on day 329 of treatment). Osteosarcomas were not reported in a published chronic dietary study of up to 130 weeks of EDTMP in Fisher 344 rats, at dietary doses up to 100 mg/kg/day (not the maximum tolerated dose). However, at study termination in female Fisher 344 rats, this dose was associated with statistically significantly higher rate of pancreatic islet-cell adenomas and carcinomas.

The results of the following genotoxicity assays with non-radioactive samarium- EDTMP were negative: Salmonella reverse mutation (AMES) assay, unscheduled DNA synthesis in rat liver primary cell culture, chromosomal aberration assay in rat lymphocytes, CHO/HGPRT forward mutation assay, and mouse bone marrow micronucleus test.

Studies have not been performed to assess the effect of QUADRAMET® on fertility.

PREGNANCY

Pregnancy Category D. See Warnings Section.

NURSING MOTHERS

It is not known whether QUADRAMET® is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from QUADRAMET® , a decision should be made whether to continue nursing or to administer the drug. If QUADRAMET® is administered, formula feedings should be substituted for breast feedings.

PEDIATRIC USE

Safety and effectiveness in pediatric patients below the age of 16 years have not been established.

ADVERSE EVENTS

Adverse events were evaluated in a total of 580 patients who received QUADRAMET® in clinical trials. Of the 580 patients, there were 472 men and 108 women with a mean age of 66 (range 20 to 87).

Of these patients, 472 (81%) had at least one adverse event. In a subgroup of 399 patients who received QUADRAMET® 1.0 mCi/kg, there were 23 deaths and 46 serious adverse events. The deaths occurred an average of 67 days (9 to 130) after QUADRAMET®. Serious events occurred an average of 46 days (1 — 118) after QUADRAMET®. Although most of the patient deaths and serious adverse events appear to be related to the underlying disease, the relationship of end stage disease, marrow invasion by cancer cells, previous myelotoxic treatment and QUADRAMET® toxicity can not be easily distinguished. In clinical studies, two patients with rapidly progressive prostate cancer developed thrombocytopenia and died 4 weeks after receiving QUADRAMET®. One of the patients showed evidence of disseminated intravascular coagulation (DIC); the other patient experienced a fatal cerebrovascular accident, with a suspicion of DIC. The relationship of the DIC to the bone marrow suppressive effect of Samarium is not known. Marrow toxicity occurred in 277 (48%) patients (See Warnings section).

In controlled studies, 7% of patients receiving 1.0 mCi/kg QUADRAMET® (as compared to 6% of patients receiving placebo) reported a transient increase in bone pain shortly after injection (flare reaction). This was usually mild, self-limiting, and responded to analgesics.

The most common adverse events observed in controlled clinical studies of QUADRAMET® , are given in Table 6.

TABLE 6 SELECTED ADVERSE EVENTS REPORTED IN ≥ 1.0 % OF PEOPLE WHO RECEIVED QUADRAMET® OR PLACEBO IN CONTROLLED CLINICAL TRIALS

ADVERSE EVENT

Placebo
N = 90

QUADRAMET®
1.0 mCi/kg
N = 199

# Patients with Any Adverse Event

72 (80%)

169 (85%)

Body As A Whole

56 (62%)

100 (50%)

Pain Flare Reaction

5 (5.6%)

14 (7.0%)

Cardiovascular

19 (21%)

32 (16%)

Arrhythmias

2 (2.2%)

10 (5.0%)

Chest Pain

4 (4.4%)

8 (4.0%)

Hypertension

0

6 (3.0%)

Hypotension

2 (2.2%)

4 (2.0%)

Digestive

44 (49%)

82 (41%)

Abdominal Pain

7 (7.8%)

12 (6.0%)

Diarrhea

3 (3.3%)

12 (6.0%)

Nausea &/or Vomiting

37 (41.1%)

65 (32.7%)

Hematologic & Lymphatic

12 (13%)

54 (27%)

Coagulation Disorder

0

3 (1.5%)

Hemoglobin Decreased

21 (23.3%)

81 (40.7%)

Leukopenia

6 (6.7%)

118(59.3%)

Lymphadenopathy

0

4 (2.0%)

Thrombocytopenia

8 (8.9%)

138(69.3%)

Any Bleeding Manifestations*

8 (8.9%)

32 (16.1%)

Ecchymosis

1 (1.1%)

3 (3.0%)

Epistaxis

1 (1.1%)

4 (2.0%)

Hematuria

3 (3.3%)

10 (5%)

Infection

10 (11.1%)

34 (17.1%)

Fever and/or Chills

10 (11.1%)

17 (8.5%)

Infection, Not Specified

4 (4.4%)

14 (7.0%)

Oral Moniliasis

1 (1.1%)

4 (2.0%)

Pneumonia

1 (1.1%)

3 (1.5%)

Musculoskeletal

28 (31%)

55 (27%)

Myasthenia

8 (8.9%)

13 (6.5%)

Pathologic Fracture

2 (2.2%)

5 (2.5%)

Nervous

39 (43%)

59 (30%)

Dizziness

1 (1.1%)

8 (4.0%)

Paresthesia

7 (7.8%)

4 (2.0%)

Spinal Cord Compression

5 (5.5%)

13 (6.5%)

Cerebrovascular Accident/Stroke

0

2 (1.0%)

Respiratory

24 (27%)

35 (18%)

Bronchitis/Cough Increased

2 (2.2%)

8 (4.0%)

Special Senses

11 (12%)

11 (6%)

Skin & Appendages

17 (19%)

13 (7%)

Purpura

0

2 (1%)

Rash

2 (2.2%)

2 (1%)

*Includes hemorrhage (gastrointestinal, ocular) reported in <1%.

In an additional 200 patients who received QUADRAMET® in uncontrolled clinical trials, adverse events that were reported at a rate of ≥ 1.0% were similar except for 9 (4.5%) patients who had agranulocytosis. Other selected adverse events that were reported in <1% of the patients who received QUADRAMET® 1.0 mCi/kg in any clinical trial include: alopecia, angina, congestive heart failure, sinus bradycardia, and vasodilation.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.